clover factors (tff) for the treatment of chronic lung diseases. The present invention provides methods for improving or inducing epithelial airway repair and / or regeneration and / or for normalizing epithelial airway remodeling using a deposition of one or more pro-regenerative factors, preferably a peptide or protein of the epithelium. clover family factor family (tff). pro-regenerative factor is administered to a patient as a treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, asthma, bronchiectasis, panbronchiolitis, pneumonia, ventilator-associated pneumonia (vap), hospital acquired pneumonia (hap ), community-acquired pneumonia (cap), severe community-acquired pneumonia (scap) and pneumonia carinii or for patients suffering from lung damage by reducing the function of the mucociliary transport system based on the complete functioning of the secondary cilia for, for example, inhalation of toxic gases. The present invention also provides prophylactic or preventive therapy, i.e. prophylaxis based on a predefined group of patient-type interventions in smoking patients in order to increase continuous repair of epithelial airways and / or regeneration of respiratory lashes improving mucociliary clearance. The pro-regenerative factor is administered intra-tracheal, intra-broncheal, intra-alveolar or bronchial-alveolar. administration, for example by inhalation of an aerosol or as a powder and / or administered as a bronchoalveolar lavage (balloon) an effective amount of the agent.fatores de trevo (tff) para o tratamento de doenças pulmonares crônicas. a presente invenção proporciona métodos para melhorar ou induzir um reparo epitelial pelas vias aéreas e/ou regeneração e/ou para a normalização da remodelação das vias aéreas epiteliais, usando uma deposição de um ou mais fatores pró-regenerativos, preferencilamente um peptídeo ou proteína da família de fator familiar de trevo (tff). o fator pró-regenerativo é administrado
